Welcome, Guest. Please login or register.
July 22, 2024, 06:43:35 pm

Login with username, password and session length

  • Total Posts: 55130
  • Total Topics: 4851
  • Online Today: 204
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 36
Total: 36


Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Hepatitis C Treatment Does Not Appear to Affect Liver Cancer Recurrence  (Read 7616 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 784
    • Hep Mag
Among those who have had a complete response to treatment for hepatocellular carcinoma (HCC, the most common form of liver cancer), treating hepatitis C virus (HCV) with direct-acting antivirals (DAAs) does not affect the risk of the cancer’s recurrence during a median follow-up time of 10 months, Healio reports. This is promising news, suggesting that DAAs are safe to use among those who have been treated for liver cancer.

Publishing their findings in the journal Gastroenterology, researchers analyzed data on 793 people who had completely responded to liver cancer treatment and who had HCV. A total of 304 of them received DAA treatment and 489 did not. During a median follow-up period of 10.4 months, there were 416 liver cancer recurrences among the study population, including 128 in those treated with DAAs and 288 in those not treated for HCV.



© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.